MTOR and glioblastoma: As PTEN expression is reduced by mutation or loss of heterozygocity in 5-40% and 60-80%, respectively [11], and PI3K/Akt/mTOR signaling is elevated in ~88% of all glioblastoma [12, 13], the addition of pharmacological inhibitors to current treatment schedules should lead to clear therapeutic benefits.